151 related articles for article (PubMed ID: 28512031)
1. From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.
Liang J; Labadie S; Zhang B; Ortwine DF; Patel S; Vinogradova M; Kiefer JR; Mauer T; Gehling VS; Harmange JC; Cummings R; Lai T; Liao J; Zheng X; Liu Y; Gustafson A; Van der Porten E; Mao W; Liederer BM; Deshmukh G; An L; Ran Y; Classon M; Trojer P; Dragovich PS; Murray L
Bioorg Med Chem Lett; 2017 Jul; 27(13):2974-2981. PubMed ID: 28512031
[TBL] [Abstract][Full Text] [Related]
2. Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies.
Liang J; Zhang B; Labadie S; Ortwine DF; Vinogradova M; Kiefer JR; Gehling VS; Harmange JC; Cummings R; Lai T; Liao J; Zheng X; Liu Y; Gustafson A; Van der Porten E; Mao W; Liederer BM; Deshmukh G; Classon M; Trojer P; Dragovich PS; Murray L
Bioorg Med Chem Lett; 2016 Aug; 26(16):4036-41. PubMed ID: 27406798
[TBL] [Abstract][Full Text] [Related]
3. Identification of potent, selective KDM5 inhibitors.
Gehling VS; Bellon SF; Harmange JC; LeBlanc Y; Poy F; Odate S; Buker S; Lan F; Arora S; Williamson KE; Sandy P; Cummings RT; Bailey CM; Bergeron L; Mao W; Gustafson A; Liu Y; VanderPorten E; Audia JE; Trojer P; Albrecht BK
Bioorg Med Chem Lett; 2016 Sep; 26(17):4350-4. PubMed ID: 27476424
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design and discovery of potent and selective KDM5 inhibitors.
Nie Z; Shi L; Lai C; O'Connell SM; Xu J; Stansfield RK; Hosfield DJ; Veal JM; Stafford JA
Bioorg Med Chem Lett; 2018 May; 28(9):1490-1494. PubMed ID: 29627262
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy.
Miyake Y; Itoh Y; Hatanaka A; Suzuma Y; Suzuki M; Kodama H; Arai Y; Suzuki T
Bioorg Med Chem; 2019 Mar; 27(6):1119-1129. PubMed ID: 30745098
[TBL] [Abstract][Full Text] [Related]
6. An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells.
Vinogradova M; Gehling VS; Gustafson A; Arora S; Tindell CA; Wilson C; Williamson KE; Guler GD; Gangurde P; Manieri W; Busby J; Flynn EM; Lan F; Kim HJ; Odate S; Cochran AG; Liu Y; Wongchenko M; Yang Y; Cheung TK; Maile TM; Lau T; Costa M; Hegde GV; Jackson E; Pitti R; Arnott D; Bailey C; Bellon S; Cummings RT; Albrecht BK; Harmange JC; Kiefer JR; Trojer P; Classon M
Nat Chem Biol; 2016 Jul; 12(7):531-8. PubMed ID: 27214401
[TBL] [Abstract][Full Text] [Related]
7. Design and evaluation of 1,7-naphthyridones as novel KDM5 inhibitors.
Labadie SS; Dragovich PS; Cummings RT; Deshmukh G; Gustafson A; Han N; Harmange JC; Kiefer JR; Li Y; Liang J; Liederer BM; Liu Y; Manieri W; Mao W; Murray L; Ortwine DF; Trojer P; VanderPorten E; Vinogradova M; Wen L
Bioorg Med Chem Lett; 2016 Sep; 26(18):4492-4496. PubMed ID: 27499454
[TBL] [Abstract][Full Text] [Related]
8. Identification of ryuvidine as a KDM5A inhibitor.
Mitsui E; Yoshida S; Shinoda Y; Matsumori Y; Tsujii H; Tsuchida M; Wada S; Hasegawa M; Ito A; Mino K; Onuki T; Yoshida M; Sasaki R; Mizukami T
Sci Rep; 2019 Jul; 9(1):9952. PubMed ID: 31289306
[TBL] [Abstract][Full Text] [Related]
9. Structural Basis for KDM5A Histone Lysine Demethylase Inhibition by Diverse Compounds.
Horton JR; Liu X; Gale M; Wu L; Shanks JR; Zhang X; Webber PJ; Bell JSK; Kales SC; Mott BT; Rai G; Jansen DJ; Henderson MJ; Urban DJ; Hall MD; Simeonov A; Maloney DJ; Johns MA; Fu H; Jadhav A; Vertino PM; Yan Q; Cheng X
Cell Chem Biol; 2016 Jul; 23(7):769-781. PubMed ID: 27427228
[TBL] [Abstract][Full Text] [Related]
10. Discovery of KDM5A inhibitors: Homology modeling, virtual screening and structure-activity relationship analysis.
Wu X; Fang Z; Yang B; Zhong L; Yang Q; Zhang C; Huang S; Xiang R; Suzuki T; Li LL; Yang SY
Bioorg Med Chem Lett; 2016 May; 26(9):2284-8. PubMed ID: 27020306
[TBL] [Abstract][Full Text] [Related]
11. Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.
Hua Z; Bregman H; Buchanan JL; Chakka N; Guzman-Perez A; Gunaydin H; Huang X; Gu Y; Berry V; Liu J; Teffera Y; Huang L; Egge B; Emkey R; Mullady EL; Schneider S; Andrews PS; Acquaviva L; Dovey J; Mishra A; Newcomb J; Saffran D; Serafino R; Strathdee CA; Turci SM; Stanton M; Wilson C; Dimauro EF
J Med Chem; 2013 Dec; 56(24):10003-15. PubMed ID: 24294969
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Highly Isoform Selective Orally Bioavailable Phosphoinositide 3-Kinase (PI3K)-γ Inhibitors.
Pemberton N; Mogemark M; Arlbrandt S; Bold P; Cox RJ; Gardelli C; Holden NS; Karabelas K; Karlsson J; Lever S; Li X; Lindmark H; Norberg M; Perry MWD; Petersen J; Rodrigo Blomqvist S; Thomas M; Tyrchan C; Westin Eriksson A; Zlatoidsky P; Öster L
J Med Chem; 2018 Jun; 61(12):5435-5441. PubMed ID: 29852070
[TBL] [Abstract][Full Text] [Related]
13. Optimization of potent, selective, and orally bioavailable pyrrolodinopyrimidine-containing inhibitors of heat shock protein 90. Identification of development candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide.
Zehnder L; Bennett M; Meng J; Huang B; Ninkovic S; Wang F; Braganza J; Tatlock J; Jewell T; Zhou JZ; Burke B; Wang J; Maegley K; Mehta PP; Yin MJ; Gajiwala KS; Hickey MJ; Yamazaki S; Smith E; Kang P; Sistla A; Dovalsantos E; Gehring MR; Kania R; Wythes M; Kung PP
J Med Chem; 2011 May; 54(9):3368-85. PubMed ID: 21438541
[TBL] [Abstract][Full Text] [Related]
14. PF-04859989 as a template for structure-based drug design: identification of new pyrazole series of irreversible KAT II inhibitors with improved lipophilic efficiency.
Dounay AB; Anderson M; Bechle BM; Evrard E; Gan X; Kim JY; McAllister LA; Pandit J; Rong S; Salafia MA; Tuttle JB; Zawadzke LE; Verhoest PR
Bioorg Med Chem Lett; 2013 Apr; 23(7):1961-6. PubMed ID: 23466229
[TBL] [Abstract][Full Text] [Related]
15. Discovery and structural optimization of pyrazole derivatives as novel inhibitors of Cdc25B.
Chen HJ; Liu Y; Wang LN; Shen Q; Li J; Nan FJ
Bioorg Med Chem Lett; 2010 May; 20(9):2876-9. PubMed ID: 20363629
[TBL] [Abstract][Full Text] [Related]
16. Structure-Guided Discovery of Novel, Potent, and Orally Bioavailable Inhibitors of Lipoprotein-Associated Phospholipase A2.
Liu Q; Huang F; Yuan X; Wang K; Zou Y; Shen J; Xu Y
J Med Chem; 2017 Dec; 60(24):10231-10244. PubMed ID: 29193967
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a novel series of potent and orally bioavailable phosphoinositide 3-kinase γ inhibitors.
Leahy JW; Buhr CA; Johnson HW; Kim BG; Baik T; Cannoy J; Forsyth TP; Jeong JW; Lee MS; Ma S; Noson K; Wang L; Williams M; Nuss JM; Brooks E; Foster P; Goon L; Heald N; Holst C; Jaeger C; Lam S; Lougheed J; Nguyen L; Plonowski A; Song J; Stout T; Wu X; Yakes MF; Yu P; Zhang W; Lamb P; Raeber O
J Med Chem; 2012 Jun; 55(11):5467-82. PubMed ID: 22548342
[TBL] [Abstract][Full Text] [Related]
18. Discovery and optimization of RO-85, a novel drug-like, potent, and selective P2X3 receptor antagonist.
Brotherton-Pleiss CE; Dillon MP; Ford AP; Gever JR; Carter DS; Gleason SK; Lin CJ; Moore AG; Thompson AW; Villa M; Zhai Y
Bioorg Med Chem Lett; 2010 Feb; 20(3):1031-6. PubMed ID: 20045645
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of a novel, orally active GSK-3 inhibitor 6-Methyl-N-[3-[[3-(1-methylethoxy)propyl]carbamoyl]-1H-pyrazol-4-yl]pyridine-3-carboxamide in tau transgenic mice.
Uno Y; Iwashita H; Tsukamoto T; Uchiyama N; Kawamoto T; Kori M; Nakanishi A
Brain Res; 2009 Nov; 1296():148-63. PubMed ID: 19698704
[TBL] [Abstract][Full Text] [Related]
20. Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A kinase.
Prime ME; Courtney SM; Brookfield FA; Marston RW; Walker V; Warne J; Boyd AE; Kairies NA; von der Saal W; Limberg A; Georges G; Engh RA; Goller B; Rueger P; Rueth M
J Med Chem; 2011 Jan; 54(1):312-9. PubMed ID: 21128645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
